SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.99-5.9%1:29 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: aknahow who wrote (10331)6/3/1999 11:16:00 PM
From: Slugger  Read Replies (2) of 17367
 
The 4 were not part of the 62. They did enter the trial and did receive either the placebo or BPI but died almost immediately. I explained why Castello made a point about this. No one knew at that time in which arm they fell.

If patients were removed from the trial because they died shortly after receiving BPI or placebo, then isn't it possible that that could skew the results to make placebo look better. Lets say the study removes patients who die within 10 minutes of receiving treatment, if BPI works as well as indicated during PII then the BPI patients would be more likely to survive the first ten minutes than the placebo. There would then be more placebo patients dying and being removed from the study than those on BPI. Of course, if the drug is clearly that good then the rest of the study should still see BPI showing good results, but not nearly as good as it should be showing (and hopefully enough to show a statistical significance).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News